Related Experiment Video
Updated: Oct 26, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.9K
Assessing Toxicity in Drug Trials in Liver Disease
1Research Administration, University Health Network, Toronto, Canada.
Seminars in Liver Disease
|July 28, 2021
Summary
Assessing drug-induced liver injury in clinical trials is vital, as hepatotoxicity halts many new drugs. This review examines current assessment systems, highlighting inaccuracies and proposing improvements for better drug safety evaluation.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Drug Development
Background:
- Drug-induced liver injury (DILI) is a significant challenge in developing new therapeutics for liver diseases.
- Hepatotoxicity is a primary reason for drug candidate failure during clinical trials.
- Accurate assessment of DILI is critical for advancing novel liver disease treatments.
Purpose of the Study:
- To review current systems for assessing drug-induced liver injury in clinical trials.
- To identify and discuss the limitations and inaccuracies of existing DILI assessment criteria.
- To propose improvements for more effective DILI evaluation in drug development.
Main Methods:
- Systematic literature review of DILI assessment criteria used in clinical trials.
- Critical analysis of the appropriateness and accuracy of established DILI diagnostic criteria.
- Comparative evaluation of different assessment methodologies.
Main Results:
- Current DILI assessment criteria in clinical trials often exhibit inaccuracies and inappropriateness.
- Existing systems may not adequately capture the nuances of drug-induced liver injury.
- Specific criteria require refinement to improve sensitivity and specificity in trial settings.
Conclusions:
- Refinement of DILI assessment criteria is essential for accurate drug safety evaluation in clinical trials.
- Improved assessment methodologies will enhance the identification of potential hepatotoxins.
- Optimized DILI evaluation supports the successful development of safer drugs for liver diseases.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
37
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
37
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
37
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
32
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
32
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
38
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
38
01:22Bioavailability: Influencing Factors
116
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
116
01:16Hepatic Drug Excretion: Influencing Factors
291
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
291